Imcyse SA
Antoon van Oosterhout is currently serving as VP R&D - CSO at Imcyse SA since January 2020. Before this role, they were a Professor of Immunology of Lung Diseases at University Medical Center Groningen. They also held the position of VP and Head Allergic Inflammation DPU at GlaxoSmithKline. Antoon's career in academia includes being an Associate Professor at Utrecht University. They possess a MSc in Medical Biology from Utrecht University and have completed a Masterclass in Biobusiness. Antoon van Oosterhout's expertise lies in the field of immunology, particularly related to lung diseases.
Imcyse SA
Imcyse is a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases. The company’s unique technology platform can address a wide range of autoimmune and immunologic diseases. Imotopes™ are modified synthetic peptides, which specifically block improper immune activity. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no effective therapeutic alternative and has the potential to cure patients without impairing their immune defenses. Our vision is to become a leader in the field of active specific immunotherapy and to prevent, stop and potentially cure autoimmune diseases. Headquartered in Liège, Belgium, Imcyse was founded as a spin-off of the Catholic University of Leuven (KULeuven). Imcyse’s Imotope™ technology platform is protected by a robust, international intellectual property portfolio. Our lead Imotope™, IMCY-0098, is in phase 2 clinical testing for early onset type 1 diabetes.